Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Haemonetics (HAE) Net Margin (2016 - 2025)

Haemonetics (HAE) has 17 years of Net Margin data on record, last reported at 13.2% in Q4 2025.

  • For Q4 2025, Net Margin rose 243.0% year-over-year to 13.2%; the TTM value through Dec 2025 reached 13.31%, up 384.0%, while the annual FY2025 figure was 12.32%, 334.0% up from the prior year.
  • Net Margin reached 13.2% in Q4 2025 per HAE's latest filing, up from 11.82% in the prior quarter.
  • Across five years, Net Margin topped out at 17.54% in Q1 2025 and bottomed at 4.91% in Q2 2021.
  • Average Net Margin over 5 years is 8.63%, with a median of 9.72% recorded in 2023.
  • Peak YoY movement for Net Margin: tumbled -1677bps in 2021, then surged 1160bps in 2025.
  • A 5-year view of Net Margin shows it stood at 6.19% in 2021, then skyrocketed by 74bps to 10.79% in 2022, then decreased by -14bps to 9.29% in 2023, then rose by 16bps to 10.77% in 2024, then increased by 23bps to 13.2% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 13.2% in Q4 2025, 11.82% in Q3 2025, and 10.59% in Q2 2025.